Dynavax Technologies reported $64.6M in EBITDA for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US USD -55733000 15.79M
Amgen AMGN:US USD 3.04B 460M
AstraZeneca AZN:LN USD 3.32B 283M
Astrazeneca AZN:US USD 3.32B 283M
Biogen BIIB:US USD 998.8M 6M
Biomarin Pharmaceutical BMRN:US USD 53K 22.33M
Bristol Myers Squibb BMY:US USD 4.66B 663M
Chimerix CMRX:US USD -23789000 35.46M
Dynavax Technologies DVAX:US USD 64.6M 1.88M
Gilead Sciences GILD:US USD 2.7B 662M
Glaxosmithkline GSK:US GBP 1.6B 1.76B
Idera Pharmaceuticals IDRA:US USD -3686000 1.67M
Minerva Neurosciences NERV:US USD -5063000 142K
Nektar Therapeutics NKTR:US USD -37707000 2.91M
Neurocrine Biosciences NBIX:US USD 107.8M 16M
Novartis NOVN:VX USD 4.5B 193M
Pfizer PFE:US USD 6.94B 3.94B
Roche Holding ROG:VX 10.43B 3B
Sarepta Therapeutics SRPT:US USD -96280000 24.37M
Tg Therapeutics TGTX:US USD -51989000 17.1M